CBCA/CBC-Enriched Cannabis Compositions for Consistent Pain Relief
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The variability in cannabis compositions due to genetic and growing conditions leads to inconsistent medical treatment outcomes for pain management, posing a challenge in standardizing effective cannabis-based therapies.
Innovation Solution
Cannabis compositions enriched with CBCA and/or CBC at specific concentrations, along with optional cannflavin A, are formulated to provide consistent pain relief across different types of pain, including orthopedic, neuropathic, and chronic pain, by ensuring a predetermined minimal amount and ratio of these compounds.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If cannabis compositions are used for pain management, then pain relief is achieved, but treatment consistency varies due to genetic and growing condition diversity
Solution Approach 1:
The patent applies parameter changes by establishing specific concentration ranges for CBCA (0.1-20% w/w) and CBC (0.05-10% w/w) in cannabis compositions. By defining precise compositional parameters, the invention transforms variable cannabis material into a standardized treatment with predictable pain relief effects, resolving the contradiction between natural composition variability and treatment consistency requirements
Solution Approach 2:
The patent applies local quality by enriching specific cannabinoid components (CBCA and CBC) within the cannabis composition while maintaining other components at natural levels. This selective enrichment ensures consistent pain relief through targeted concentration of therapeutic compounds, addressing the reliability issue without requiring complete standardization of the entire composition
2Manufacturing precision
If cannabis compositions with varying CBCA/CBC content are used, then different pain relief effects are observed, but standardizing treatment protocols becomes difficult
Solution Approach 1:
The patent simplifies treatment protocol complexity by establishing clear, measurable parameters for CBCA (0.1-20% w/w) and CBC (0.05-10% w/w) content. These defined parameters create straightforward manufacturing and quality control protocols, eliminating the need for complex individualized treatment plans while ensuring consistent therapeutic outcomes across different batches and products
Data Source
Figure 1
Figure 2A
Figure 2B
AI summary
Disclosed are cannabis compositions including CBCA and/or CBC at or above a predetermined minimal concentration that provides a consistent therapeutic effect, and methods of using the same, for treating pain.